RCS - Ondine Biomedical - Steriwave now in Canada's East Coast

Ondine BiomedicalAnnouncement

13/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231013:nRSM9925Pa&default-theme=true

RNS Number : 9925P  Ondine Biomedical Inc.  13 October 2023

13 October 2023

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 Steriwave now in Canada's East Coast

Nova Scotia's largest hospital is the latest to implement Steriwave nasal
photodisinfection for use prior to orthopedic surgery

Canadian life sciences company Ondine Biomedical's (LON: OBI) Steriwave®
nasal photodisinfection for the prevention of healthcare-associated infections
(HAIs) is now available in hospitals across Canada. The latest hospital to
implement Steriwave for its orthopedic surgery patients is the Queen Elizabeth
II Health Sciences Centre in Halifax, affiliated with Dalhousie University and
the largest hospital in Nova Scotia, located on Canada's East Coast.

Steriwave is a highly effective method of preventing infections following
surgery. This is particularly important due to growing concern about
antimicrobial resistance (AMR), as hospitals must adapt their protocols to
combat the rapid rise of drug-resistant pathogens.

One in nine hospital patients in Canada gets a healthcare-associated infection
(HAI) resulting in around 12,000 deaths a year.( 1  (#_edn1) ) HAIs are also
becoming harder to treat due to rising rates of antimicrobial resistance (AMR)
which are making some commonly used antibiotics ineffective.( 2  (#_edn2) )
This has meant that one in 19 deaths in Canada is now attributable to
antibiotic-resistant infections.( 3  (#_edn3) ) The cost of AMR to the
Canadian healthcare sector is also projected to increase from $1.4 billion to
$7.6 billion per year by 2050.( 4  (#_edn4) )

Ondine Biomedical's CEO Carolyn Cross said:

"It is hugely satisfying that Steriwave is now available in hospitals from
coast to coast across Canada, giving patients enhanced protection against
post-surgical infections. This new hospital deployment demonstrates
Steriwave's growing status as an effective alternative to topical antibiotics
for infection prevention that easily fits into existing hospital workflows. In
the US we are continuing to move forward with our Phase 3 trial in partnership
with HCA Healthcare who are providing invaluable input and support."

Ondine's nasal photodisinfection treatment kills all types of pathogens -
viruses, bacteria, and fungi - without causing resistance and is already in
use in major hospitals across Canada, including Vancouver General and UBC
Hospitals in BC, The Ottawa Hospital (Ontario), the Mazankowski Alberta Heart
Institute (Alberta), and the Montreal Heart Institute (Quebec).

Nasal photodisinfection is a non-antibiotic method for nasal decolonization
that uses a proprietary light-activated agent to destroy pathogens. First, the
agent is applied to each nostril using a nasal swab, then the area is
illuminated with a specific wavelength of light. The light activates the
photodynamic agent, causing an oxidative burst that destroys pathogens. In
this single, 5-minute treatment, Steriwave eliminates infection-causing
bacteria, viruses, and fungi in the nose.( 5  (#_edn5) )

 

**ENDS**

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the
field of photodisinfection therapies. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection platform, in various
stages of development. Products beyond nasal photodisinfection include
therapies for a variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.

About Nasal Photodisinfection

Ondine's nasal photodisinfection is a patented technology using a proprietary
photosensitizer (non-antibiotic, light-activated agent) to destroy pathogens.
The photodisinfection treatment is carried out by a trained healthcare
professional, and is an easy-to-use, painless, two-step process. The
photosensitizer is applied to each nostril using a nasal swab, followed by
illumination of the area with a specific wavelength of laser light for less
than five minutes. The light activates the photosensitizer, causing an
oxidative burst that is lethal to all types of pathogens. A key benefit of
this approach, unlike with antibiotics, is that pathogens do not develop
resistance to the therapy.

Nasal decolonization with antibiotics is already standard practice in many
hospitals prior to surgery, as pathogens in a patient's nasal cavities are a
major cause of surgical site infections (SSIs). However, there is a growing
need to reduce antibiotic use and find non-antibiotic methods of nasal
decolonization as resistance rates have been reported as high as 81%.( 6 
(#_edn6) )

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and
is approved in Canada and several other countries under the name Steriwave®.
It has been used in Canada for over ten years, with no serious adverse events
reported. In the US, it is currently undergoing clinical trials for regulatory
approval.

 1  (#_ednref1)
https://cupe.ca/health-care-associated-infections-backgrounder-and-fact-sheet
(https://cupe.ca/health-care-associated-infections-backgrounder-and-fact-sheet)

 2  (#_ednref2) Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance:
clinical implications and potential alternatives for the eradication of MRSA.
J Antimicrob Chemother. 2015 Oct;70(10):2681-92. doi: 10.1093/jac/dkv169. Epub
2015 Jul 3.

 3  (#_ednref3) Healthcare-associated infections and antimicrobial resistance
in Canadian acute care hospitals, CCDR 49(5) - Canada.ca

 4  (#_ednref4) Healthcare-associated infections and antimicrobial resistance
in Canadian acute care hospitals, CCDR 49(5) - Canada.ca

 5  (#_ednref5) Liu Z, Norman G, Iheozor-Ejiofor Z, Wong JK, Crosbie EJ,
Wilson P. Nasal decontamination for the prevention of surgical site infection
in Staphylococcus aureus carriers. Cochrane Database Syst Rev. 2017 May
18;5(5):CD012462. doi: 10.1002/14651858.CD012462.pub2. PMID: 28516472; PMCID:
PMC6481881.

 6  (#_ednref6) Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance:
clinical implications and potential alternatives for the eradication of MRSA.
J Antimicrob Chemother. 2015 Oct;70(10):2681-92. doi: 10.1093/jac/dkv169. Epub
2015 Jul 3.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFLDIILFLIV